C4 Therapeutics, Inc. (CCCC)
3.17
+0.32
(+11.23%)
USD |
NASDAQ |
Oct 09, 16:00
3.17
0.00 (0.00%)
After-Hours: 17:35
C4 Therapeutics Enterprise Value : 153.48M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 153.48M |
| October 07, 2026 | 149.79M |
| October 06, 2026 | 157.16M |
| October 05, 2026 | 170.68M |
| October 02, 2026 | 165.77M |
| October 01, 2026 | 189.12M |
| September 30, 2026 | 212.47M |
| September 29, 2026 | 187.89M |
| September 28, 2026 | 186.05M |
| September 25, 2026 | 169.45M |
| September 24, 2026 | 175.60M |
| September 23, 2026 | 181.74M |
| September 22, 2026 | 210.01M |
| September 21, 2026 | 208.78M |
| September 18, 2026 | 219.85M |
| September 17, 2026 | 222.92M |
| September 16, 2026 | 227.22M |
| September 15, 2026 | 224.76M |
| September 14, 2026 | 224.76M |
| September 11, 2026 | 234.59M |
| September 10, 2026 | 221.07M |
| September 09, 2026 | 225.99M |
| September 08, 2026 | 239.51M |
| September 04, 2026 | 265.32M |
| September 03, 2026 | 262.86M |
| Date | Value |
|---|---|
| September 02, 2026 | 269.01M |
| September 01, 2026 | 278.84M |
| August 31, 2026 | 259.18M |
| August 28, 2026 | 276.38M |
| August 27, 2026 | 307.11M |
| August 26, 2026 | 324.32M |
| August 25, 2026 | 319.40M |
| August 24, 2026 | 307.11M |
| August 21, 2026 | 294.82M |
| August 20, 2026 | 298.51M |
| August 19, 2026 | 320.63M |
| August 18, 2026 | 316.94M |
| August 17, 2026 | 327.39M |
| August 14, 2026 | 324.32M |
| August 13, 2026 | 304.65M |
| August 12, 2026 | 282.53M |
| August 11, 2026 | 278.84M |
| August 10, 2026 | 248.11M |
| August 07, 2026 | 261.63M |
| August 06, 2026 | 250.57M |
| August 05, 2026 | 248.11M |
| August 04, 2026 | 246.88M |
| August 03, 2026 | 233.37M |
| July 31, 2026 | 230.91M |
| July 30, 2026 | 253.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.400B |
| Arrowhead Pharmaceuticals, Inc. | 8.347B |
| Oncolytics Biotech, Inc. | 64.19M |
| Sangamo Therapeutics, Inc. | 49.79M |
| Sarepta Therapeutics, Inc. | 2.181B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.64M |
| Revenue (Quarterly) | 6.641M |
| Total Expenses (Quarterly) | 30.28M |
| EPS Diluted (Quarterly) | -0.1808 |
| Gross Profit Margin (Quarterly) | 73.05% |
| Profit Margin (Quarterly) | -355.9% |
| Earnings Yield | -31.51% |
| Normalized Earnings Yield | -28.24 |